SCHEMBL20181563

SCHEMBL20181563

CCc1nc2cc(O)ccn2c1C(=O)c1ccc(O)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 6/20 0.39
EYA3 Q99504 2/20 0.39
NPC1 O15118 3/20 0.36
RAB9A P51151 3/20 0.36
HTT P42858 2/20 0.36
HDAC1 Q13547 1/20 0.36
ESR1 P03372 1/20 0.36
ESR2 Q92731 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 1/20 0.34
CLK1 P49759 2/20 0.34
DYRK1A Q13627 2/20 0.34
DYRK1B Q9Y463 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20181565 0.87 SLC22A12 (0.43) SLC22A12NPC1RAB9AHTTLMNA
SCHEMBL18629834 0.84 MAPK1 (0.50) NPC1HPGDMEN1KMT2ASMN1; SMN2
SCHEMBL20181666 0.82 MAPT (0.43) RAB9AHTTESR1ESR2LMNA
SCHEMBL22623471 0.81 MAPK1 (0.36) SLC22A12EYA3NPC1RAB9AHTT
SCHEMBL18629887 0.79 HTT (0.37) SLC22A12EYA3NPC1RAB9AHTT
SCHEMBL22623466 0.79 ESR1 (0.36) SLC22A12EYA3HTTESR1ESR2
SCHEMBL20181564 0.79 LMNA (0.43) NPC1RAB9AHTTLMNAMAPT
SCHEMBL21191865 0.78 HDAC1 (0.33) SLC22A12EYA3NPC1RAB9AHTT
SCHEMBL20181584 0.76 MAPK1 (0.48) NPC1RAB9AHTTESR1ESR2
SCHEMBL20181614 0.74 ALDH1A1 (0.50) SLC22A12EYA3RAB9AHTTESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE50083-E1 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2024-08-20 US disclosed
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-03-07 US disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3543240-B1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-07-06 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
EP-3632904-B1 URAT1 INHIBITORS FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO LTD (CN) 2022-04-20 EP disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-10875865-B2 URAT1 inhibitor and use thereof JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-12-29 US disclosed
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-08-20 US disclosed
EP-3632904-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2020-04-08 EP disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2020-02-27 US disclosed
EP-3543240-A1 URAT1 INHIBITOR AND USE THEREOF Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. (CN) 2019-09-25 EP disclosed
WO-2018090921-A1 URAT1 INHIBITOR AND USE THEREOF 江苏新元素医药科技有限公司 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11597725-B2 URAT1 inhibitor for promoting uric acid excretion SLC10A6, SLC10A1, SLC28A1 SLC22A12 35/4885EYA3 2625/4885NPC1 163/4885
US-20200062763-A1 URAT1 INHIBITOR AND USE THEREOF SLC14A1, SLC10A6, SLC10A1 SLC22A12 39/4885EYA3 2921/4885NPC1 150/4885
US-10875865-B2 URAT1 inhibitor and use thereof SLC14A1, SLC10A6, SLC10A1 SLC22A12 39/4885EYA3 2921/4885NPC1 150/4885
US-20200262832-A1 URAT1 INHIBITOR FOR PROMOTING URIC ACID EXCRETION SLC10A6, SLC10A1, SLC28A1 SLC22A12 35/4885EYA3 2625/4885NPC1 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.